New study below [1].
Note: AA = Abiraterone acetate/Zytiga
"We conducted a post hoc analysis of individual patient data of CRPC patients treated with prednisone and/or AA with or without statins/vitamin D on randomized clinical trials."
"In the COU-AA-301 trial, use of AA with statin and vitamin D reduced the risk of death by 38% ... while AA alone was associated with a decrease of 10% .., compared to prednisone alone."
"... in the COU-AA-302 trial, use of AA plus statin plus vitamin D was associated with a reduced risk of death of 26% ..."
"In this data analysis from two prospective randomized clinical trials, statin and vitamin D use was associated with superior overall survival in metastatic CRPC patients treated with AA and prednisone."
-Patrick
pubmed.ncbi.nlm.nih.gov/321...
Clin Transl Oncol
2020 Mar 20[Online ahead of print]
Combination of Statin/Vitamin D and Metastatic Castration-Resistant Prostate Cancer (CRPC): A Post Hoc Analysis of Two Randomized Clinical Trials
A Carretero-González 1 , D Lora 2 , R Manneh 3 , D Lorente 4 , D Castellano 1 , G de Velasco 5
Affiliations collapse
Affiliations
1 Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain.
2 Clinical Research Unit, IMAS12-CIBERESP, University Hospital 12 de Octubre, Madrid, Spain.
3 Oncology and Hematology Society From Cesar, Valledupar, Colombia.
4 Medical Oncology Department, Hospital Provincial de Castellón, Castellón de la Plana, Spain.
5 Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain. gdvelasco.gdv@gmail.com.
PMID: 32198642 DOI: 10.1007/s12094-020-02334-6
Abstract
In castration-resistant prostate cancer (CRPC) patients, observational studies have reported that statins may boost the antitumor activity of abiraterone (AA) and data suggest an improvement in efficacy; conclusions with vitamin D are less clear but an eventual benefit has been pointed. We conducted a post hoc analysis of individual patient data of CRPC patients treated with prednisone and/or AA with or without statins/vitamin D on randomized clinical trials. In the COU-AA-301 trial, use of AA with statin and vitamin D reduced the risk of death by 38% (p = 0.0007) while AA alone was associated with a decrease of 10% (p = 0.025), compared to prednisone alone. Meanwhile, in the COU-AA-302 trial, use of AA plus statin plus vitamin D was associated with a reduced risk of death of 26% (p = 0.0054). In this data analysis from two prospective randomized clinical trials, statin and vitamin D use was associated with superior overall survival in metastatic CRPC patients treated with AA and prednisone. To our knowledge, this is the first report suggesting the impact of statin plus vitamin D in this population. New strategies using big data may help to clarify these questions easily and in a most cost-effective approach.
Keywords: Abiraterone; Castration-resistant prostate cancer; Statins; Survival; Vitamin D.